Home › Compare › AKRFF vs ABBV
AKRFF yields 2063.98% · ABBV yields 3.06%● Live data
📍 AKRFF pulled ahead of the other in Year 1
Combined, AKRFF + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of AKRFF + ABBV for your $10,000?
Ackroo Inc. develops and sells an online loyalty and rewards platform that enables businesses to design and execute customer transaction, engagement, and retention strategies primarily in North America. It enables small to medium sized businesses to automate the processing and management of gift card and loyalty transactions to increase profitability and build long-term customer relationships. The company's cloud-based marketing platform provides merchants an in-store and online process to manage loyalty, gift card, and promotional transactions at the point of sale; a program to help them view data for reconciliation, reporting, and marketing; and customer interfaces to allow merchant's consumers to register, check, transfer, and reload balances. It also provides AckrooPOS/GGGolf platform for golf clubs, which integrates accounting and hospitality point of sale options and other services; and offers handicapping services, as well as to manage tee-sheets, lottery, and tournaments. In addition, the company offers marketing services, including email and direct mail marketing, and design services; and payment services comprising credit and debit card processing services. It serves automotive, petroleum, hospitality, and retail markets. Ackroo Inc. was founded in 2012 and is headquartered in Hamilton, Canada.
Full AKRFF Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.